Related Experiment Video
Updated: Aug 14, 2026
10:47
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Engineered single chain antibody fragments for radioimmunotherapy
1Cancer Research UK Imaging and Targeting Group, Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom. a.huhalov@ucl.ac.uk
Summary
Antibody engineering optimizes radioimmunotherapy (RIT) molecules for targeted cancer treatment. This approach uses engineered antibody fragments for improved tumor targeting and reduced side effects.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Radioimmunotherapy (RIT) requires molecules with high tumor specificity and concentration, alongside rapid clearance from normal tissues.
- Ideal RIT agents should also be non-immunogenic to prevent adverse reactions.
- Current RIT strategies can be improved by leveraging advanced protein engineering techniques.
Purpose of the Study:
- To review the application of antibody engineering in designing effective RIT molecules.
- To highlight the use of single chain Fv (scFv) antibody fragments as key components in RIT drug development.
Main Methods:
- Focus on antibody engineering techniques for protein design.
- Utilizing single chain Fv (scFv) fragments as foundational elements.
- Rational design principles for optimizing RIT agent characteristics.
Main Results:
- Antibody engineering enables the creation of RIT molecules with enhanced tumor targeting.
- Engineered proteins demonstrate improved pharmacokinetic profiles, including prolonged tumor residence time and rapid normal tissue clearance.
- The development of non-immunogenic RIT agents is facilitated through protein engineering.
Conclusions:
- Antibody engineering is a powerful strategy for developing next-generation RIT agents.
- scFv fragments are versatile building blocks for creating targeted and safe RIT therapeutics.
- Optimized RIT molecules hold significant promise for improving cancer treatment outcomes.
